Samsung Biologics and LigaChem extend ADC services deal
Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The partnership will leverage Samsung Biologics'…
All articles by Vishnu Priya N
Vishnu Priya N
-
-
Aspect Biosystems secures $115m to develop tissue therapeutics
Aspect Biosystems has secured $115m in a Series B financing round to advance the development of bioprinted tissue therapeutics. Multistage…
-
Immedica to buy Marinus Pharmaceuticals for $151m
Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m. Marinus…
-
FDA approves BMS’ Opdivo Qvantig for solid tumour indications
The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for subcutaneous use…
-
Mankind Pharma and Innovent partner for Sintilimab commercialisation in India
Mankind Pharma has entered into a partnership with Innovent Biologics for exclusively licensing and commercialising Sintilimab, an immunotherapy for cancer…
-
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
AstraZeneca and Daiichi Sankyo have withdrawn their marketing authorisation application in the European Union (EU) voluntarily, intended for datopotamab deruxtecan…
-
Booster Therapeutics to develop proteasome activator medicines
Booster Therapeutics has announced its inception, backed by a $15m investment, to develop a new class of proteasome activator medicines…
-
KeyBioscience and Eli Lilly extend partnership for obesity treatments
Nordic Bioscience subsidiary KeyBioscience has announced an extension of its strategic partnership with Eli Lilly, focusing on the development of…
-
Merck unveils $318m biosafety testing facility in Maryland, US
Germany-based Merck KGaA has announced the launch of a new €290m ($317.6m) biosafety testing facility in Rockville, Maryland, US. The…
-
Arda Therapeutics secures $43m to develop cell depletion therapies
Arda Therapeutics has secured $43m in Series A financing to develop targeted cell depletion therapies. Andreessen Horowitz (a16z Bio +…